Skip to main content
. 2024 Mar 26;60(4):539. doi: 10.3390/medicina60040539

Figure 2.

Figure 2

Effects of anti-ORAIP mAb on body weight loss, shortening of colon length, and disease activity. (A,C) Time course of the relative body weight (A) and Disease Activity Index (DAI) score (C) in anti-ORAIP mAb-treated group and mouse IgG-treated control group. (B) Colon length in the two groups at sacrifice on day 10. The differences between the mouse IgG-treated control group and anti-ORAIP mAb-treated group were significant (* p < 0.01 (A), * p < 0.05 (B) and * p < 0.01 (C), respectively).